Albion Financial Group UT lessened its holdings in Allergan PLC. (NYSE:AGN) by 0.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,939 shares of the company’s stock after selling 59 shares during the period. Allergan PLC. accounts for approximately 1.3% of Albion Financial Group UT’s portfolio, making the stock its 26th largest holding. Albion Financial Group UT’s holdings in Allergan PLC. were worth $8,007,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rockshelter Capital Management LLC lifted its stake in shares of Allergan PLC. by 0.6% during the second quarter. Rockshelter Capital Management LLC now owns 50,472 shares of the company’s stock valued at $12,269,000 after buying an additional 323 shares during the period. Wafra Investment Advisory Group Inc. NY purchased a new position in shares of Allergan PLC. during the second quarter valued at approximately $14,524,000. Stonebridge Capital Advisors LLC lifted its stake in shares of Allergan PLC. by 1.4% during the second quarter. Stonebridge Capital Advisors LLC now owns 11,413 shares of the company’s stock valued at $2,774,000 after buying an additional 155 shares during the period. 361 Capital LLC lifted its stake in shares of Allergan PLC. by 5.5% during the second quarter. 361 Capital LLC now owns 28,380 shares of the company’s stock valued at $6,899,000 after buying an additional 1,475 shares during the period. Finally, Quadrant Capital Group LLC lifted its stake in shares of Allergan PLC. by 1.4% during the second quarter. Quadrant Capital Group LLC now owns 1,201 shares of the company’s stock valued at $235,000 after buying an additional 16 shares during the period. 81.94% of the stock is currently owned by institutional investors.

WARNING: “Albion Financial Group UT Sells 59 Shares of Allergan PLC. (AGN)” was first reported by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/10/18/albion-financial-group-ut-sells-59-shares-of-allergan-plc-agn.html.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the firm earned $3.35 earnings per share.

Allergan PLC. declared that its Board of Directors has authorized a stock repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 2.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Several brokerages recently issued reports on AGN. Vetr raised shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective on the stock in a research note on Monday, June 26th. Wells Fargo & Company reissued an “outperform” rating and set a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. UBS AG set a $255.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Tuesday. Deutsche Bank AG set a $251.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Tuesday. Finally, Credit Suisse Group set a $243.00 price objective on shares of Allergan PLC. and gave the company an “outperform” rating in a research note on Tuesday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $266.69.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.